Minerva Neurosciences | NERV - Selling And Administration Expenses


Minerva Neurosciences reported $2.48M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
Adma Biologics USD 26.74M 6.55M Mar/2026
ALKERMES USD 196.64M 67.96M Jun/2026
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
AstraZeneca USD 5.8B 735M Jun/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.43M 222K Mar/2026
CSL USD 1.23B 498M Dec/2025
Eli Lilly USD 3.43B 496M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Grifols EUR 320.45M 12.65M Dec/2025
Halozyme Therapeutics USD 57M 10.71M Jun/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
J&J USD 6.42B 381M Jun/2026
Merck USD 2.89B 219M Jun/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 3.41B 496M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.63B 307M Jun/2026
Takeda JPY 286.51B 5.48B Jun/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024